Situation
Axios-managed Patient Assistance Programs (PAPs) have supported patients in Malaysia for nearly 20 years, helping them obtain a full course of treatment at a cost they can afford. But affordability and timing are two different problems. Even patients approved for support often face a gap between the moment they need to start treatment and the moment funds or reimbursement actually come through, and for chronic or urgent conditions, every week of delay carries real clinical consequences.
Malaysia required a new access model that would not only improve treatment affordability, but also make it possible for patients to start treatment without delay, without affecting existing reimbursement pathways in the country.
Solution
To overcome these critical barriers, Axios utilized its On-Time Access (OTA) model, a new solution that complements Axios-managed PAPs by not only improving affordability, but also ensuring patients can begin treatment without delay and stay on treatment.
Patients enrolled in an Axios-managed PAP receive a personalized plan outlining how much financial support they will receive to cover the cost of their full course of treatment, and how much they may need to contribute themselves. The level of financial support received by each patient is based on their financial capacity, as assessed through Axios’ proprietary, validated Patient Financial Evaluation Tool (PFET).
If patients enrolled in the program faced cash flow challenges or reimbursement delays that were making it difficult for them to cover their share of the treatment cost, and hence delays in starting or continuing treatment, OTA stepped in, utilizing two models:
- Partial Contribution Assistance: Provides financial support to cover part or all of the patient’s share of treatment costs when they cannot afford it.
- Cash Gap Support: Provides zero-interest funding to cover the patient’s share of their treatment costs until personal funds or reimbursement become available, with repayment through a transparent, personalized plan.
The Malaysia rollout also shows a specific Axios strength: the ability to embed a global model into local health system infrastructure rather than operating alongside it. After the first patient enrolled in December 2024, OTA was formally integrated into the Malaysia Ministry of Health (MOH) Lung Health Initiative by February 2025, and broader in-country implementation was approved by September 2025.
Results
By August 2026, the program had reached nationwide momentum: 12 states, 15 hospitals and pharmacies, 57 referring physicians, and 1,342 treatment packs supported, with documented impact on the MOH Blue Book Formulary. Next, OTA will support additional indications, products, and disease areas across Malaysia, continuing a pattern consistent with Axios’s broader footprint of access programs across more than 100 countries, reaching over 10 million people.
